Healios KK (JP:4593) has released an update.
Healios K.K. has published a study in ‘Stem Cell Research & Therapy’ demonstrating that their hypoimmunogenic human induced pluripotent stem cells (iPSCs) can evade immune responses, positioning them as a promising source for regenerative medicine. These gene-edited Universal Donor Cells (UDCs) can differentiate into various cell types while retaining a safety switch, enhancing their therapeutic potential with reduced immune rejection risks. The company continues to pioneer regenerative therapies, providing UDCs globally for diseases lacking effective treatments.
For further insights into JP:4593 stock, check out TipRanks’ Stock Analysis page.
